Create Transformative Medicines


Precision Lethal Therapies

Critical cellular functions have redundant mechanisms to ensure cell viability (e.g. two genes with similar function). Oncogenic events can lead to loss of one of the genes making the remaining gene essential (synthetic lethal). Targeting a synthetic lethal interaction beyond DNA damage repair results in selective tumor cell death while sparing healthy normal cells (precision lethal).

Our Portfolio

Riva’s portfolio is the result of a 4-year collaboration with the Broad Institute of MIT and Harvard. Our targets have been extensively validated and regulate essential oncogenic processes including a subset previously thought to be “undruggable”.

Our Research Alliance

Our Research Alliance evolved from the Novo Broad Greenhouse, a joint initiative between Novo Ventures and the Broad Institute of MIT and Harvard. Our ongoing Research Alliance accelerates our precision lethality approach through a combination of deep drug discovery expertise, world-class cancer biology, access to proprietary platform technologies, and continued insights from our scientific co-founders (William C. Hahn, MD, PhD; Francisca Vazquez, PhD; Andrew Aguirre, MD, PhD; Kent Mouw, MD, PhD; Eliezer Van Allen, MD; Peter Tsvetkov, PhD).

Contact Us

Riva Therapeutics

9276 Scranton Rd. Suite 500

San Diego, CA 92121

Phone: (858) 227-4141